- Home
- MYGN vs XNCR Comparison
MYGN vs XNCR Comparison
Compare MYGN & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- XNCR
- Stock Information
- Founded
- MYGN 1991
- XNCR 1997
- Country
- MYGN United States
- XNCR United States
- Employees
- MYGN N/A
- XNCR N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- MYGN Health Care
- XNCR Health Care
- Exchange
- MYGN Nasdaq
- XNCR Nasdaq
- Market Cap
- MYGN 744.7M
- XNCR 625.6M
- IPO Year
- MYGN 1995
- XNCR 2013
- Fundamental
- Price
- MYGN $4.13
- XNCR $8.06
- Analyst Decision
- MYGN Hold
- XNCR Buy
- Analyst Count
- MYGN 16
- XNCR 9
- Target Price
- MYGN $16.40
- XNCR $30.13
- AVG Volume (30 Days)
- MYGN 3.4M
- XNCR 998.0K
- Earning Date
- MYGN 05-06-2025
- XNCR 05-07-2025
- Dividend Yield
- MYGN N/A
- XNCR N/A
- EPS Growth
- MYGN N/A
- XNCR N/A
- EPS
- MYGN N/A
- XNCR N/A
- Revenue
- MYGN $831,300,000.00
- XNCR $127,228,000.00
- Revenue This Year
- MYGN N/A
- XNCR N/A
- Revenue Next Year
- MYGN $7.21
- XNCR $25.05
- P/E Ratio
- MYGN N/A
- XNCR N/A
- Revenue Growth
- MYGN 7.38
- XNCR N/A
- 52 Week Low
- MYGN $3.98
- XNCR $7.16
- 52 Week High
- MYGN $29.30
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- MYGN 25.47
- XNCR 36.87
- Support Level
- MYGN $3.81
- XNCR $7.89
- Resistance Level
- MYGN $4.31
- XNCR $8.39
- Average True Range (ATR)
- MYGN 0.47
- XNCR 0.82
- MACD
- MYGN -0.16
- XNCR -0.12
- Stochastic Oscillator
- MYGN 8.00
- XNCR 5.45
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.